Iohexol Zentiva (Iohexol)

Iohexol contains multiple iodine atoms that strongly absorb X‑ray photons. When injected into the bloodstream or administered intrathecally, the iodine increases the attenuation of X‑rays passing through the targeted area, creating a temporary contrast difference that enhances the radiographic image of vascular and tissue structures.

The dose of Iohexol Zentiva is determined by the prescribing physician based on the specific imaging procedure, patient weight, renal function, and the required level of contrast. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal imaging while minimizing risk.

The safety of Iohexol Zentiva in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Iohexol Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Iohexol Zentiva is a non‑ionic, low‑osmolality iodinated contrast medium, offering a lower incidence of adverse reactions compared with older, high‑osmolality ionic agents. Its safety profile, image quality, and versatility across intra‑arterial, intravenous, and intrathecal routes make it a preferred choice for many diagnostic imaging applications.

Iohexol Zentiva should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for particulate matter before use.

Iohexol Zentiva is administered by a qualified healthcare professional via intra‑arterial, intravenous, or intrathecal injection, depending on the imaging study. The injection is typically performed using a sterile technique, and the volume is adjusted to the specific diagnostic requirement and patient characteristics.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment especially in patients with pre‑existing kidney disease, and rare neurological events like seizures. Prompt recognition and management of these reactions are essential, and patients should be monitored closely during and after administration.

Iohexol Zentiva should be avoided in patients with a known allergy to iodine or iodinated contrast media, those with severe uncontrolled hyperthyroidism, and individuals with markedly impaired renal function where the risk of contrast‑induced nephropathy outweighs diagnostic benefit. Clinical judgment is required for each case.